All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On April 1, 2022, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) for adult patients with large B-cell lymphoma (LBCL) who have relapsed within 12 months of, or who are refractory to, first-line chemoimmunotherapy.1 This change in authorization could expand the pool of those eligible for CAR T-cell therapy by up to 11,000 patients in the U.S. alone.1 LBCL is the most commonly diagnosed form of non-Hodgkin lymphoma globally.2
The approval is based on key data obtained from the ZUMA-7 trial.
This approval could help to address an area of unmet need for patients with LBCL who do not respond well to high-dose chemoimmunotherapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?
Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R)...
EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 3 – CAR-T
A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took place on Tuesday 26 March 2019, during the 45th Annual...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox